Anixa Biosciences Says FDA Clears IND For CAR-T Immunotherapy For Ovarian Cancer - Quick Facts

(RTTNews) - Biotechnology company Anixa Biosciences, Inc. (ANIX) announced Monday that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its CAR-T (Chimeric Antigen Receptor-T cell) therapy, which is being developed in partnership with Moffitt Cancer Center.

The therapeutic product is comprised of engineered T-cells that target the follicle stimulating hormone receptor (FSHR). FSHR is found at immunologically relevant levels exclusively on the granulosa cells of the ovaries.

Anixa Biosciences can now initiate clinical trial for the ovarian cancer CAR-T immunotherapy. It has an exclusive worldwide license to the autologous cell therapy technology.

CAR-T therapy has had major successes in B-cell malignancies, but no clinical success in other types of tumors. It could be the first CAR-T approach that will demonstrate efficacy in a solid tumor indication.